AbbVie is planning to build a 185-acre pharmaceutical campus in Durham, N.C. The $1.4 billion development will integrate AI with advanced manufacturing and laboratory technologies to enhance quality control and support the company’s pipelines of immunology, neuroscience, and oncology medicines. Comprising approximately 440,000 sf, the first phase of construction will begin in 2026 to create manufacturing plants for small volume parenteral (SVP) drug products. The initial footprint will also house next-generation labs, administrative offices, and employee wellness venues, as well as a warehouse and space for future growth.
The transformative project will serve as AbbVie’s U.S. center of excellence for SVP production and supply life-saving medicines to patients throughout the country and worldwide. The state-of-the-art facility represents the firm’s largest single-site investment to date, and forms part of a $100 billion expansion program across the next decade which will also drive R&D initiatives. Located near Research Triangle Park, this dynamic pharmaceutical hub is slated for completion in 2028.
